Armistice Capital, LLC Erasca, Inc. Transaction History

Armistice Capital, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.67 - $2.55 $3.21 Million - $4.91 Million	-1,924,000 Reduced 23.76%	6,172,000 $12.7 Million
Q4 2023 Feb 13, 2024	SELL	$1.67 - $2.49 $434,200 - $647,400	-260,000 Reduced 3.11%	8,096,000 $17.2 Million
Q3 2023 Nov 14, 2023	BUY	$1.97 - $2.91 $985,000 - $1.46 Million	500,000 Added 6.36%	8,356,000 $16.5 Million
Q2 2023 Aug 14, 2023	BUY	$2.57 - $3.3 $1.3 Million - $1.67 Million	506,000 Added 6.88%	7,856,000 $21.7 Million
Q1 2023 May 15, 2023	BUY	$2.74 - $4.44 $12.7 Million - $20.6 Million	4,650,000 Added 172.22%	7,350,000 $22.1 Million
Q4 2022 Feb 14, 2023	BUY	$3.89 - $8.57 $10.5 Million - $23.1 Million	2,700,000 New	2,700,000 $11.6 Million

140

229M

28.7K

117K

Ticker ERAS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,147,000
Market Cap $289M
Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...

Get notified when there are updates to the investment portfolio of Armistice Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Armistice Capital, LLC with notifications on news.